Primary Angiitis of the Central Nervous System (PACNS) - Treatment Recommendations
For induction therapy of PACNS, treat with high-dose glucocorticoids (prednisone 1 mg/kg/day, maximum 60 mg/day) combined with cyclophosphamide (oral 2 mg/kg/day, maximum 200 mg/day, or intravenous pulse therapy), followed by maintenance immunosuppression with mycophenolate mofetil, azathioprine, or rituximab for 24 months. 1, 2, 3
Induction Therapy (First 3-6 Months)
The cornerstone of PACNS treatment mirrors the approach used for other severe vasculitides, adapted from ANCA-associated vasculitis protocols 4:
Glucocorticoid Regimen
- Start prednisone at 1 mg/kg/day (maximum 60 mg/day) 4
- Maintain this high dose for 1 month minimum
- Do not reduce below 15 mg/day for the first 3 months 4
- Consider intravenous methylprednisolone pulse therapy when rapid effect is needed 4
- Implement osteoporosis prophylaxis from day one 4
Cyclophosphamide Administration
The evidence supports cyclophosphamide as the primary induction agent 1, 3, 5:
- Oral route: 2 mg/kg/day (maximum 200 mg/day) 4
- Intravenous pulse: Alternative with potentially lower cumulative toxicity but possibly higher relapse risk 4
- Duration: Continue for 3-6 months until remission achieved 1
Critical Supportive Measures
- Pneumocystis jiroveci prophylaxis is mandatory: Use trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily 4
- Mesna administration with pulse cyclophosphamide to prevent hemorrhagic cystitis 4
- Monitor complete blood count weekly initially, then biweekly 4
Maintenance Therapy (12-24 Months)
After achieving remission, transition to maintenance immunosuppression 1, 6:
Glucocorticoid Taper
- Reduce to ≤10 mg/day during remission 4
- Continue for median 12 months total 6
- Taper gradually to avoid relapse
Maintenance Immunosuppression Options
Continue maintenance therapy for 24 months 6:
- Mycophenolate mofetil - Increasingly favored alternative 1, 7
- Azathioprine - Traditional maintenance agent 1, 7
- Rituximab - Effective for refractory or relapsing disease 1, 8, 7
- Methotrexate - Option for less severe disease 7
Special Considerations and Pitfalls
High-Risk Period for Stroke
Critical timeframe: The highest probability of ischemic stroke occurs 10-20 days after initiating immunosuppression (approximately 12% risk) 9. Patients require:
- Closer monitoring during this window
- Possible therapy adjustment if high-risk features present
- Vessels with higher stenosis degree and circular enhancement pattern carry greatest stroke risk 9
Surgical Intervention
For patients with significant mass effect, consider surgical resection in addition to medical therapy 3. Three cases showed improvement after craniotomy 3.
Refractory or Relapsing Disease
Relapse is common in PACNS 1. When disease progresses despite glucocorticoids and cyclophosphamide:
- Increase glucocorticoid dose 1
- Consider switching to rituximab 1, 8, 7
- TNF-α inhibitors show efficacy in refractory cases 10
Poor Prognostic Indicators
Patients with the following features have worse outcomes 3:
- Long disease course before diagnosis (>6 months)
- Karnofsky performance status <60 at diagnosis
- Behavioral or cognitive abnormalities before treatment
- Short-term relapse (0.3-1 month after treatment)
Monitoring Strategy
During Induction
- Weekly CBC initially, then biweekly 4
- Adjust cyclophosphamide dose for leucopenia
- Monitor renal function for dose adjustments 4
- Blood glucose monitoring on glucocorticoids 4
Long-term Follow-up
- Structured clinical examination 4
- Serial neuroimaging to detect subclinical progression 2, 9
- Consider emerging biomarkers: neurofilament light chain, sTREM2 10
Evidence Quality Note
The 2023 European Stroke Organisation guidelines emphasize that evidence quality is very low overall for PACNS management 2. Treatment recommendations are largely extrapolated from ANCA-associated vasculitis protocols 4 and expert consensus 6, 2. Despite this limitation, the glucocorticoid-cyclophosphamide combination remains standard based on consistent use across all published cohorts 1, 3, 5.
Mortality remains 8-23% despite treatment 1, 10, and approximately 25% experience severe disability 10, underscoring the need for aggressive early therapy and close monitoring.